Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Murine model for mantle cell lymphoma

Leukemia volume 20, pages 891–893 (2006)Cite this article

Mantle cell lymphoma (MCL), typically CD5+, CD23− B cells, is a particularly difficult type of non-Hodgkin's lymphoma (NHL) in that it behaves aggressively but is incurable with standard therapy.1 New therapies are clearly needed. Thus, it would be very useful to have an animal model for MCL.

Mantle cell lymphoma is characterized by the chromosome translocation t(11;14), which dysregulates expression of the cyclin D1 gene. It seemed reasonable that transgenic mice carrying Eμ-cyclinD1 should develop MCL. Surprisingly, however, such mice developed normally and failed to develop tumors.2 B-lymphocyte development appeared normal. Crossing of Eμ-cyclinD1 transgenic mice with c-myc transgenic mice led to accelerated development of an aggressive lymphoma of the type seen with c-myc alone, but not MCL,2 and c-myc is not commonly rearranged in MCL. Thus, cyclin D1 appears to be necessary, but not sufficient, for mantle cell lymphomagenesis. Therefore, additional genetic events are necessary for the development of MCL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Campo E, Raffeld M, Jaffe ES . Mantle-cell lymphoma. Semin Hematol 1999; 36: 115–127.

    CAS  Google Scholar 

  2. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM . Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994; 13: 2124–2130.

    Article  CAS  Google Scholar 

  3. Anderson PN, Potter M . Induction of plasma cell tumours in BALB-c mice with 2,6,10,14 tetramethylpentadecane (pristane). Nature 1969; 222: 994–995.

    Article  CAS  Google Scholar 

  4. Potter M, Wax JS . Peritoneal plasmacytogenesis in mice: comparison of different pristane dose regimens. J Natl Cancer Inst 1983; 1: 391–395.

    Google Scholar 

Download references

Acknowledgements

Leukemia Lymphoma Society of America Translational Grant no. 6187-03; The Lymphoma Foundation; American Cancer Society Institutional Research Grant; NIH core Grant no. CA006927; Aventis Pharmaceuticals. Additional funding was from the Janice Charach Epstein Research Fund and Lester Smith Research Fund of Fox Chase Cancer Center.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

    M R Smith, I Joshi & F Jin

  2. Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA

    T Al-Saleem

Authors
  1. M R Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Al-Saleem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M R Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, M., Joshi, I., Jin, F. et al. Murine model for mantle cell lymphoma. Leukemia 20, 891–893 (2006). https://doi.org/10.1038/sj.leu.2404177

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404177

This article is cited by

Search

Advanced search

Quick links